GeoVax Responds to Detection of Clade I Mpox in North Carolina WastewaterSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine CongressSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC OperationsRecognized Biologics Executive to Oversee Critical Expansion of U.S.-Based Development Capabilities
GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC OperationsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine CandidatesSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine CandidatesPeer-Reviewed Data Reinforces GeoVax’s Multi-Antigen Strategy With GEO-CM02 and Supports Advancement of GEO-CM04S1 Clinical Programs
GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business MomentumSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax to Present at the Emerging Growth Conference on April 16, 2025Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax to Present Clinical Data at Upcoming April Industry EventsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine PatentSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Reports 2024 Year-End Financial Results and Provides Business UpdateSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Reports 2024 Year-End Financial Results and Provides Business UpdateGEO-CM04S1 BARDA/Project NextGen Phase 2b trial preparations ongoing with manufacturing of clinical trial materials underway and clinical sites confirmed
GeoVax Labs Announces $4.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Labs Announces $4.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesATLANTA, GA - March 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for the purchase and sale of 3,435,115 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 3,435,115 shares of common stock in a registered direct offering (the "Offering") at a combined purchase price of $1.31 per share and accompanying warrant, priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $1.31 per share, will be exercisable upon shareholder approval and will expire 5 years from shareholder approval.
GeoVax to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Labs Inc. (NASDAQ: GOVX) Featured in Coverage of the 37th Annual ROTH ConferenceGeoVax Labs (
NASDAQ: GOVX) is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (“CLL”). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax’s leadership team has driven significant value creation across multiple life science companies over the past several decades.
GeoVax Establishing Strategic Presence in Europe With Initial Footprint in the UKSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax to Present at the 37th Annual Roth ConferenceSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
